''We are now in a far stronger position and are NOT reliant on...

''We are now in a far stronger position and are NOT reliant on any large pharma to take this through to registration.''



IMO

Market cap around $78m at this point in time - says a lot about how early in the game this is for measuring OS and PFS against the current best standard of care

This Latest CR is peanuts in the total upfront costs and ongoing costs and study drug costs over years


Agile Trial yet to commence on 150 plus patients initially and then towards 200 after efficacy - how many years of data will be required on varying patients trials


Newbies DYOR on registration process and costs